Arrowhead Pharmaceuticals, Inc. (ARWR)
- Previous Close
15.74 - Open
15.86 - Bid 11.32 x 200
- Ask 20.22 x 200
- Day's Range
15.62 - 16.01 - 52 Week Range
9.57 - 30.41 - Volume
222,346 - Avg. Volume
1,831,608 - Market Cap (intraday)
2.185B - Beta (5Y Monthly) 0.90
- PE Ratio (TTM)
-- - EPS (TTM)
-1.24 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
44.50
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.
arrowheadpharma.comRecent News: ARWR
View More
Performance Overview: ARWR
Trailing total returns as of 5/20/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARWR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARWR
View MoreValuation Measures
Market Cap
2.17B
Enterprise Value
1.46B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.67
Price/Book (mrq)
3.18
Enterprise Value/Revenue
2.69
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-26.41%
Return on Assets (ttm)
-5.86%
Return on Equity (ttm)
-26.22%
Revenue (ttm)
545.21M
Net Income Avi to Common (ttm)
-143.97M
Diluted EPS (ttm)
-1.24
Balance Sheet and Cash Flow
Total Cash (mrq)
1.1B
Total Debt/Equity (mrq)
108.23%
Levered Free Cash Flow (ttm)
-6.46M
Research Analysis: ARWR
View MoreResearch Reports: ARWR
View MoreRating decreased to a SELL
ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of SELL; a target price of $12.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetWhat does Argus have to say about ARWR?
ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $14.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetRaising target price to $14.00
ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $14.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetLowering target price to $13.00
ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $13.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice Target